Quest Diagnostics EBITDA Margin 2010-2024 | DGX

Quest Diagnostics ebitda margin for the quarter ending September 30, 2024 was 18.02%.

  • Quest Diagnostics average ebitda margin for 2023 was 17.43%, a 21.91% increase from 2022.
  • Quest Diagnostics average ebitda margin for 2022 was 22.32%, a 17.91% decline from 2021.
  • Quest Diagnostics average ebitda margin for 2021 was 27.19%, a 26.11% decline from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Quest Diagnostics EBITDA Margin 2010-2024 | DGX

  • Quest Diagnostics average ebitda margin for 2023 was 17.43%, a 21.91% increase from 2022.
  • Quest Diagnostics average ebitda margin for 2022 was 22.32%, a 17.91% decline from 2021.
  • Quest Diagnostics average ebitda margin for 2021 was 27.19%, a 26.11% decline from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
Fresenius SE (FSNUY)$19.5B
DaVita (DVA)$12.9B
Encompass Health (EHC)$10B
Chemed (CHE)$8.2B
Elanco Animal Health (ELAN)$6.6B
RadNet (RDNT)$5.9B
Option Care Health (OPCH)$3.7B
Amedisys (AMED)$2.9B
LifeStance Health (LFST)$2.8B
Astrana Health (ASTH)$2.3B
Addus HomeCare (ADUS)$2.2B
U.S Physical Therapy (USPH)$1.4B
Aveanna Healthcare Holdings (AVAH)$1.1B
Pennant (PNTG)$1.1B
Atai Life Sciences (ATAI)$290M
Daxor (DXR)$43M
MEDIROM Healthcare Technologies (MRM)$15M
Psychemedics (PMD)$14M
ATI Physical Therapy (ATIP)$8M
Ontrak (OTRK)$8M
IMAC Holdings (BACK)$1M